Search Results

Vistagen announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace.

The National Eczema Association announced the second publication from its real-world research on eczema and its impacts on mental health.

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc., a leader in genetic testing and precision medicine.

The Foundation for the National Institutes of Health announces that Love Collins, III, has joined as Vice President of Advancement.

A new study from researchers at Children’s Hospital of Philadelphia reveals that the cumulative “wear and tear” on the body known as allostatic load can be measured in early adolescence and that childhood adversity correlates with increased stress and mental health challenges during adolescence.

Castle Biosciences, Inc. announced that it has been selected as the winner of the “Best Overall Mental Health Solution” award in the eighth annual MedTech Breakthrough Awards program for its IDgenetix® pharmacogenomic test.

Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.

The Foundation for the National Institutes of Health announces two additions to the FNIH Board of Directors: James W. Down, former Vice Chairman of Mercer Management Consulting, and Perry Steiner, Chairman and CEO of Xactus.

The Foundation for the National Institutes of Health announces the launch of a public-private partnership to build the largest data source for amyotrophic lateral sclerosis and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development for people living with the disease.